以雷贝拉唑和兰索拉唑为基础的三联疗法治疗复发性消化性溃疡的疗效比较

The Clinic Study of the Trilogic Treatments Base on Rabeprazole or Lansoprazole Respective Effect on Palindromic Helico bacter Pylori Positive Peptic Ulcer

目的:比较以雷贝拉唑为基础的"三联疗法"与以兰索拉唑为基础的"三联疗法"治疗复发性消化性溃疡的疗效与安全性。方法:选取复发性消化性溃疡患者85例,随机分治疗组和对照组,分别给予以雷贝拉唑或以兰索拉唑为基础的三联疗法治疗,总疗程均为6周。结果:疗程结束时,治疗组总有效率为97.6%,对照组总有效率为88.4%,两组疗效差异无统计学意义(P>0.05),但是治疗组症状完全缓解天数少于对照组(P<0.05)。两组幽门螺杆菌转阴率和溃疡愈合率差异无统计学意义(P>0.05)。结论:以雷贝拉唑为基础的"三联疗法"与以兰索拉唑为基础的"三联疗法"治疗复发性消化性溃疡均安全、有效,但是以雷贝拉唑为基础的三联疗法缓解症状更快,依从性更好,是治疗复发性消化性溃疡较好的方案。

Objective：To compare the efficacy and safety of trilogic treatments base on rabeprazole or lansoprazole respective effect on palindromic helicon bacter pylori positive peptic ulcer.Methods： Selected from October 2008 to March 2010 in my out-patient and hospitalization of 85 patients with recurrent ulcer were randomly divided into two groups and were given rabeprazole and lansoprazole-based triple therapy,the total course of treatment was 6 weeks.Results： There was no significant difference comparing the total effective rate of the therapic group and the control with the rate was 97.6% and 88.4%（P0.05）,but treatment group bear fewer days to symptom complete remission（P0.05）;The eradication rate and peptic ulcer concrete rate of the two groups had no significant difference（P0.05）.Conclusions： Both the trilogic treatments base on rabeprazole and lansoprazole effect on palindromic helicon bacter pylori positive peptic ulcer are safe and effective,but the former has fewer days to symptom complete remission,and better compliance which is a better choic to palindromic helicon bacter pylori positive peptic ulcer.